BioCryst ( (BCRX)) has issued an announcement. BioCryst Pharmaceuticals reported a strong Q3 2024 with ORLADEYO net revenue of $116.3 million, growing 35.7% year-over-year, and adjusted full-year ...
Operator Good day and Welcome to the BioCryst third-quarter 2024 earnings call. [Operator instructions] Please note this ...
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on BioCryst (BCRX – Research Report), with a price ...
The drugmaker posted revenue of $117.1 million in the period, surpassing Street forecasts. Three analysts surveyed by Zacks expected $114.8 million. BioCryst expects full-year revenue in the range of ...
DURHAM, N.C. (AP) — DURHAM, N.C. (AP) — BioCryst Pharmaceuticals Inc. (BCRX) on Monday reported a loss of $14 million in its third quarter. The Durham, North Carolina-based company said it had ...
BioCryst expects full-year revenue in the range of $443 million to $448 million. BioCryst shares have risen 41% since the beginning of the year. The stock has climbed 49% in the last 12 months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback